

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Imugene Limited
<b>ABN</b>	99 009 179 551

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Paul Hopper
<b>Date of last notice</b>	19 January 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b>	Director related Parties
<b>Date of change</b>	01 February 2024
<b>No. of securities held prior to change</b>	(1) Direct Shares - 2,894,314 ORDINARY FULLY PAID SHARES (2) Indirect Shares - 317,154,000 ORDINARY FULLY PAID SHARES (3) 2,900,000 - ESOP OPTIONS (4) 2,916,666 - LISTED OPTIONS @ \$0.118, expiring 31 August 2026 (5) 3,901,500 - PERFORMANCE RIGHTS AWARD
<b>Class</b>	(1) Direct Shares - ORDINARY FULLY PAID SHARES (2) Indirect Shares - ORDINARY FULLY PAID SHARES
<b>Number acquired</b>	(1) 1,381,422 - ORDINARY FULLY PAID SHARES (Subject to voluntary escrow 12m after issue date) (2) 110,790,024 - ORDINARY FULLY PAID SHARES (Subject to voluntary escrow 12m after issue date)
<b>Number disposed</b>	(2) 10,000,000 ORDINARY FULLY PAID
<b>Value/Consideration</b>	(1) \$0.0155 PER ORDINARY FULLY PAID SHARE (2) \$0.0155 PER ORDINARY FULLY PAID SHARE

<sup>+</sup> See [chapter 19](#) for defined terms.

<b>No. of securities held after change</b>	<p>(1) Direct Shares - 4,275,736 ORDINARY FULLY PAID SHARES (1,381,422 Shares - Subject to voluntary escrow 12m after issue date)</p> <p>(2) Indirect Shares - 417,944,024 ORDINARY FULLY PAID SHARES (110,790,024 Shares - Subject to voluntary escrow 12m after issue date)</p> <p>(3) 2,900,000 - ESOP OPTIONS</p> <p>(4) 2,916,666 - LISTED OPTIONS @ \$0.118, expiring 31 August 2026</p> <p>(5) 3,901,500 - PERFORMANCE RIGHTS AWARD</p>
<b>Nature of change</b>	<p>Shares acquired: (1) and (2) Shares issued to related and unrelated party vendors of Vaxinia Pty Ltd pursuant to Resolutions 1 and 2 as approved by shareholders at the Extraordinary General Meeting of the Company held on 18 November 2019.</p> <p>Shares disposed: (2) Transfer of shares for nil consideration.</p>

## Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b>	N/A
<b>Interest after change</b>	N/A

## Part 3 - <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	NO
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See [chapter 19](#) for defined terms.